Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where EDAP declined for three days, in of 308 cases, the price declined further within the following month. The odds of a continued downward trend are .
The 10-day RSI Indicator for EDAP moved out of overbought territory on February 19, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 56 cases where EDAP's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
EDAP broke above its upper Bollinger Band on February 14, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on January 27, 2025. You may want to consider a long position or call options on EDAP as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for EDAP just turned positive on January 21, 2025. Looking at past instances where EDAP's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
EDAP moved above its 50-day moving average on January 30, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for EDAP crossed bullishly above the 50-day moving average on February 03, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EDAP advanced for three days, in of 246 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 199 cases where EDAP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EDAP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.581) is normal, around the industry mean (7.608). EDAP's P/E Ratio (100.000) is considerably higher than the industry average of (28.511). EDAP's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (4.521). EDAP has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.032). P/S Ratio (4.303) is also within normal values, averaging (33.632).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDAP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.
a developer of minimally invasive medical devices for urological diseases
Industry MedicalDistributors
A.I.dvisor tells us that EDAP and AORT have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EDAP and AORT's prices will move in lockstep.
Ticker / NAME | Correlation To EDAP | 1D Price Change % | ||
---|---|---|---|---|
EDAP | 100% | -1.63% | ||
AORT - EDAP | 29% Poorly correlated | -1.84% | ||
ENZ - EDAP | 21% Poorly correlated | +1.78% | ||
AVNS - EDAP | 21% Poorly correlated | -0.83% | ||
SRDX - EDAP | 21% Poorly correlated | +0.20% | ||
UFPT - EDAP | 20% Poorly correlated | +2.55% | ||
More |